Today's Trend
Vir Biotechnology, Inc. (NASDAQ: VIR) is under pressure as investors digest a wave of analyst forecast changes following its latest earnings miss and a fresh conference appearance. The stock appears to be moving lower on concerns that near-term profitability remains distant, even though one major analyst still has a bullish long-term view.
- HC Wainwright kept a Buy rating on Vir Biotechnology and reiterated a $20 price target, suggesting meaningful upside if the pipeline and earnings outlook improve.
- HC Wainwright raised some longer-dated outlooks, including FY2029 EPS and FY2028 EPS, which may signal improving expectations further out for Vir Biotechnology. Article Title
- Vir Biotechnology presented at the Bank of America Global Healthcare Conference 2026, which likely kept the company in focus but did not include any clearly market-moving operational update. Article Title
- HC Wainwright cut earnings estimates for multiple periods, including FY2026, FY2027, and several 2026–2027 quarters, reflecting weaker near-term profit expectations for Vir Biotechnology.
- The new forecast follows a prior earnings report in which Vir Biotechnology posted a surprise loss, reinforcing investor concerns about the company’s ability to turn profitable soon. Article Title
Overall, Vir Biotechnology (VIR) is likely trending lower because recent analyst revisions point to continued losses in the near term, even though the stock still has support from a bullish price target and some longer-term estimate upgrades.